Washington Trust Bank’s Regulus Therapeutics RGLS Stock Holding History

Washington Trust Bank’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1	Closed	–	–	834
2017 Q4	$0	Buy	+1	New	+$127	﹤0.01%	760

Other funds holding RGLS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SDIC

South Dakota Investment Council Sioux Falls, South Dakota $5.24B AUM 22.1% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ascend Capital Orinda, California $1.99B AUM 10.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Washington Trust Bank's RGLS Position: Q1 2018 in Review

Washington Trust Bank sold out of Regulus Therapeutics (RGLS) in Q1 2018, closing a stake of 1 share.

Washington Trust Bank first reported a position in RGLS in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 50 funds tracked by Wall St. Rank hold RGLS as of Q1 2018.

Washington Trust Bank reported no remaining Regulus Therapeutics position as of Q1 2018 after selling out during the quarter.
Washington Trust Bank sold 1 Regulus Therapeutics share in Q1 2018.
Washington Trust Bank first reported a position in Regulus Therapeutics in Q4 2017 and held it in 1 quarter.
Washington Trust Bank's Regulus Therapeutics position peaked at $0 in Q4 2017.
50 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q1 2018.

Based on Washington Trust Bank's 13F filing for Q1 2018, filed 3 Apr 2018.